View more job listings or post a job
Boston Biomedical Inc SR/Clinical Research Scientist - Clinical Development - Oncology 
Applied Molecular Transport (AMT) Research Associate, Pharmacology/Biology
Applied Molecular Transport (AMT) Senior Scientist, Pharmacology/Biology
RAPT Therapeutics Research Associate, DMPK
Jazz Pharmaceuticals Senior Manager, Clinical Pharmacology
Nektar Therapeutics Research Associate III
Nektar Therapeutics Sr. Scientist, Bioanalytical
Genentech, Inc. Associate Scientist/Scientist, Drug Metabolism and Pharmacokinetics
Jubilant Discovery Services Senior Manager Business Development
Post a job


In Vitro Diagnostics (IVD) & Companion Diagnostics (CDx): Guiding Clinical Trials and Patient Treatment through Precision Medicine

Speakers: Eric Fung (GRAIL), Sharon Pitteri (Stanford), Hua-Fen Liu (Dian Diagnistics), Chris Apfel (Sage Medic), Sean Zhang (Johns Hopkins), Kunbin Qu (Beigene), Mark Girardi (Boston Healthcare), Wen Huang (Vela Diagnostics)
Organizers: Hui Xu and Wen Huang
Date: 2019-12-10
Time: 8:45-17:00 Pacific Time
Registration fee (USD):
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Crown Bio;(Major Sponsorship - afternoon session still open)
Vendor show vendors registered to date: (2)PHC former Panasonic Healthcare; Viitai
Registration deadline:2019-12-10  (it will close sooner if the seating cap is reached)

About the Topic

Precision medicine aims to tailor disease prevention and treatment considering differences in individual's genes, environments, and lifestyles. This symposium will review the progress in this field that enable clinicians to quickly, efficiently and accurately predict the most appropriate course of action for a patient and help drug developers to select the right patients for the clinical trials to maximize the probability of clinical success.



Section 1: Methods (NGS, proteomics, metabolomics, functional test)

Section 2: Application highlights (CDx, Pathology)

Section 3: Development (commercial, assay)

8:45 - 9:00  PBSS Welcome Remarks

9:00 - 9:20  Introduction and field overview (Hui Xu, CPO, InterVenn Biosciences) 

9:20 - 10:05  Multi-cancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay (Eric Fung, Senior Group Medical Director, GRAIL)

10:15 - 10:25  major Sponsor's presentation - Crown Bioscience

10:25 10:40  Coffee break

10:40 to 11:25  Proteomics and Glycoproteomics for Diagnostics (Sharon Pitteri, Associate Professor Of Radiology (Cancer Early Detection-Canary Center), Stanford University)

11:25-12:10  The opportunities and challenges of Metabolomics biomarkers discovery and development in clinical diagnostics (Hua-Fen Liu, CEO, Calibra Diagnostics)

12:10-1:00  Lunch break

1:00-1:45  Overcoming limitations of next generation sequencing using functional profiling (Chris Apfel, CEO, Sage Medic)

1:45-2:30  Infectious disease applications (Sean Zhang, Associate Professor of Pathology, Johns Hopkins University)

2:30-2:45  Coffee break

2:45-3:15  CDx for clinical trials and drug development (Kunbin Qu, Director of Cancer Genomics, Beigene)

3:15-4:00  Companion Diagnostics in Immuno-Oncology: Global Commercial and Partnership Considerations (Mark Girardi, SVP, Boston Healthcare)

4:00-4:45  Assay development: from research to clinics (Wen Huang, CTO & Head of Early Research (Global), Vela Diagnostics)

4:45-5:15  Q&A session and closing remarks

2020-01-10, All about half-life: which one should I use? (tentative title)
2020-01-21, Considerations for Successful Clinical Development: Fundamentals and Best Practices for Clinical Trial Design, Biostatistics, and Data Management
2020-02-11, Development of Drug/Device Combinations
2020-02-24, MS Courses by Dr. Jack Henion: Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
2020-03-09, Animal Pharmacology Models for Oncology Drug Development
2020-03-16, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
2020-04-10, Development of Multivalent Protein Conjugates as a Strategy to Engineer Drug Pharmacology
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-05-22, No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 12/5/2019; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Origin Bioanalytical Laboratory Sacramento-based CRO for bioanalytical method development, validation, and consulting of LC-MS/MS analysis, specializing in ocular matrices
Adesis Inc. Adesis provides expertise in custom synthesis, process dev, R&D, and specialty mfg. to pharma, chemical, biomaterials, and catalysts companies
Pacific BioLabs Bay Area CRO with 37 years experience in Methods Development & Validation, Bioanalysis, Toxicology, Immunogenicity, Stability Studies & Microbiology
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS & GC-MS/MS bioanalytical quantitation services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad